for46
mAbexperimentalADC
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 30, 2018 (NCT03575819)
Timeline
Indications
Mechanism of action
- Membrane cofactor proteinINHIBITOR
CD46 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06842498 | Phase 2 | Mar 1, 2025 | FibroGen |
| NCT05011188 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2021 | Fortis Therapeutics, Inc., University of California, San Francisco, University of San Francisco |
| NCT03650491 | Phase 1 | Nov 30, 2018 | Fortis Therapeutics, Inc. |
| NCT03575819 | Phase 1 | Sep 30, 2018 | Fortis Therapeutics, Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Fortis Therapeutics, Inc. | For profit | 3 | 2 | 2 | 2018 |
| FibroGen | For profit | 1 | 1 | 1 | 2025 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of San Francisco | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1